Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research report report published on Monday, Benzinga reports. Needham & Company LLC currently has a $2.50 price objective on the stock. Separately, Cantor Fitzgerald lowered their target price on shares of Lucid Diagnostics from $3.80 to […]